Post-marketing drug withdrawals can be associated with various events, ranging from safety
issues such as reported deaths or severe side-effects, to a multitude of non-safety problems …

In 2014, the National Institutes of Health (NIH) initiated the Illuminating the Druggable Genome
(IDG) program to identify and improve our understanding of poorly characterized proteins …

The Illuminating the Druggable Genome (IDG) project aims to improve our understanding of
understudied proteins and our ability to study them in the context of disease biology by …

Regular monitoring of drug regulatory agency web sites and similar resources for information
on new drug approvals and changes to legal status of marketed drugs is impractical. It …

Computational methods to predict molecular properties regarding safety and toxicology
represent alternative approaches to expedite drug development, screen environmental …

The rise of novel artificial intelligence (AI) methods necessitates their benchmarking against
classical machine learning for a typical drug-discovery project. Inhibition of the potassium …

The United States has a complex regulatory scheme for marketing drugs. Understanding drug
regulatory status is a daunting task that requires integrating data from many sources from …

Background With a constant increase in the number of new chemicals synthesized every
year, it becomes important to employ the most reliable and fast in silico screening methods to …

Pharos is an integrated web‐based informatics platform for the analysis of data aggregated
by the Illuminating the Druggable Genome (IDG) Knowledge Management Center, an NIH …

Drug-induced inhibition of the human ether-à-go-go-related gene (hERG)-encoded potassium
ion channels can lead to fatal cardiotoxicity. Several marketed drugs and promising drug …